August 22, 2024
The Globe and Mail | Ex-Chinook team launches Borealis Biosciences with $150-million from Novartis, Versant
Brian Bloom, Chairman and Chief Executive Officer of Bloom Burton & Co. comments in the following Globe and Mail coverage on the launch of Borealis Biosciences, a startup focused on developing RNA medicines to fight kidney disease.
Borealis Biosciences’ founding team includes recognizable names from Chinook Therapeutics, which was bought in 2023 by Novartis (SWX: NOVN) for US$3.5 billion.
